Page last updated: 2024-11-04

rizatriptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rizatriptan is a selective 5-HT1B/1D receptor agonist used to treat migraine headaches. Its synthesis involves several steps, starting with the reaction of a substituted indole with a protected 2-chloro-4-nitrophenyl acetic acid. The resulting intermediate is then subjected to a series of transformations, including deprotection, amination, and cyclization, to obtain rizatriptan. When administered, rizatriptan binds to serotonin receptors in the brain, constricting blood vessels and reducing the inflammation associated with migraine headaches. It is widely studied due to its effectiveness in treating migraine, its relatively fast onset of action, and its potential for oral administration. The research on rizatriptan has focused on understanding its mechanism of action, exploring its efficacy and safety, and developing new formulations for better patient compliance.'

rizatriptan: structure given in first source; RN given refers to benzoate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5078
CHEMBL ID905
CHEBI ID48273
SCHEMBL ID26662
MeSH IDM0246872

Synonyms (68)

Synonym
AC-1712
BIDD:GT0361
bdbm50033437
AB00698277-07
gtpl51
l-705126
n,n-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1h-indole-3-yl)ethylamine
144034-80-0
n,n-dimethyl-2-[5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethanamine
rizatriptan [inn:ban]
1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-
rizatriptan
n,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]-ethanamine
risatriptan
n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indole-3-ethanamine
DB00953
NCGC00095899-01
SPECTRUM1505189
mk 462 free base
CHEBI:48273 ,
rizatriptanum
mk-462 free base
CHEMBL905 ,
L000812
D08485
rizatriptan (inn)
n,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethanamine
A808161
unii-51086hbw8g
51086hbw8g ,
dtxsid2023565 ,
tox21_111534
cas-144034-80-0
dtxcid103565
rizatriptan benzoat
2-(5-((1h-1,2,4-triazol-1-yl)methyl)-1h-indol-3-yl)-n,n-dimethylethanamine
NCGC00095899-04
rizatriptan [mi]
rizatriptan [inn]
rizatriptan [vandf]
rizatriptan [who-dd]
dimethyl({2-[5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethyl})amine
AKOS015896596
STL484039
AB00698277-05
smr000469172
MLS006010229
SCHEMBL26662
dimethyl-[2-(5-[1,2,4]triazol-1-ylmethyl-1h-indol-3-yl)-ethyl]-amine
Q-201675
AB00698277_09
AB00698277_08
SBI-0206745.P001
n,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl] ethylamine
FT-0704226
DS-15263
BCP28039
Q212171
orphenadrinehydrochloride
BRD-K75699339-057-03-2
NCGC00095899-15
NCGC00095899-09
4-(1h-1,2,4-triazole-1-yl-methyl)anilinehydrochloride
dimethyl(2-{5-[(1h-1,2,4-triazol-1-yl)methyl]-1h-indol-3-yl}ethyl)amine
EN300-7382446
n,n-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl)-ethanamine
n,n-dimethyl-2-(5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl)ethanamine
n02cc04

Research Excerpts

Overview

Rizatriptan benzoate is a 5 HT 1B/1D receptor agonist which is prescribed for the treatment of migraine. The drug is a second-generation triptan marketed as 5 and 10 mg tablets and rapidly disintegrating wafer formulations.

ExcerptReferenceRelevance
"Rizatriptan benzoate is a 5 HT 1B/1D receptor agonist which is prescribed for the treatment of migraine. "( Development and validation of UV spectrophotometric method to study stress degradation behaviour of rizatriptan benzoate.
Amolkumar, K; Ashok, T; Kiran, J, 2015
)
2.08
"Rizatriptan is a selective 5-HT1B/1D agonist approved for the acute treatment of migraine. "( Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment.
Diamond, M; Diamond, S; Freitag, F; Janssen, I; Rodgers, A; Skobieranda, F, 2008
)
2.04
"Rizatriptan is an effective treatment for MRM. "( A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine.
Bigal, M; Ho, TW; Rapoport, A; Sheftell, F; Tepper, D; Tepper, S, 2008
)
2.05
"Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes. "( Spotlight on rizatriptan in migraine.
Jarvis, B; Wellington, K, 2002
)
2.13
"Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. "( Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
Allen, C; Christie, S; Göbel, H; Mateos, V; Shivaprakash, M; Vrijens, F, 2003
)
2.01
"Rizatriptan is a second-generation triptan marketed as 5 and 10 mg tablets and rapidly disintegrating wafer formulations. "( A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine.
Pascual, J, 2004
)
2.15
"Rizatriptan is a highly potent, selective serotonin 5-HT(1B/1D)-receptor agonist. "( [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance].
Aijima, H; Ikemoto, F; Natsumeda, Y; Toru, T, 2004
)
2.68
"Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. "( Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine.
Bigal, ME; Krymchantowski, AV, 2004
)
3.21
"Rizatriptan is a selective agonist of the 5-hydroxytryptophan(1B/1D )receptors, with proven superiority over placebo, ergotamine and selected oral triptans, demonstrating a good profile of safety and tolerability."( Rizatriptan in migraine.
Bigal, ME; Krymchantowski, AV, 2005
)
2.49
"Rizatriptan (MK-462) is a new 5-hydroxytryptamine1D (serotonin1D; 5-HT1D) receptor agonist for the acute treatment of migraine that has improved pharmacokinetic properties compared with sumatriptan succinate."( Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Ferrari, MD; Jiang, K; Lines, CR; Reines, SA; Terwindt, GM; Visser, WH, 1996
)
3.18
"Rizatriptan (MK-462) is a novel 5-HT1D-receptor agonist and is effective in the treatment of migraine headache. "( Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols.
Boulanger, CM; Brown, MJ; Desta, B; Ferro, A; Hargreaves, RJ; Hill, RG; Longmore, J; Schofield, WN; Taylor, AA,
)
1.8
"Rizatriptan (MK-462) is a potent 5HTID receptor agonist. "( Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
Block, G; Ferrari, MD; Gijsman, H; Kramer, MS; Matzura-Wolfe, D; Polis, A; Sargent, J; Teall, J; Tuchman, M, 1997
)
1.99
"Rizatriptan is a novel 5-HT1B/1D agonist which is rapidly absorbed after oral administration. "( Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
Block, G; Cutler, N; Gross, M; Jiang, K; Reines, S; Smith, B; Teall, J; Tuchman, M; Willoughby, E, 1998
)
3.19
"Rizatriptan is a potent and rapidly absorbed 5-HT1B/1D receptor agonist. "( A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.
Amaraneni, PG; Feighner, J; Getson, A; Kramer, MS; Matzura-Wolfe, D; McHugh, W; Polis, A; Reines, SA; Silberstein, S; Solbach, MP, 1998
)
2.01
"Rizatriptan is a potent, highly selective 5HT1B/1D agonist with rapid onset of action for acute treatment of migraine. "( Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.
Ahrens, SP; Block, GA; Farmer, MV; Jiang, K; Visser, WH; Williams, DL; Willoughby, E, 1999
)
2.06
"Rizatriptan is an orally active serotonin 5-HT1 receptor agonist selective for the 5-HT(1B/1D) subtypes. "( Rizatriptan: a review of its efficacy in the management of migraine.
Dooley, M; Faulds, D, 1999
)
3.19
"Rizatriptan is a novel 5-HT1D/1B agonist for relief of migraine headache. "( Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects.
Brucker, MJ; Ermlich, SJ; Goldberg, MR; Lee, Y; McLoughlin, DA; Olah, TV; Panebianco, D; Shadle, CR; Slaughter, DE; Vyas, KP, 2000
)
3.19
"Rizatriptan is a selective 5-hydroxytriptamine1B/1D receptor agonist that was launched in 1998 for the acute treatment of migraine in adults. "( Rizatriptan in the treatment of migraine.
Dahlof, CG; Lines, CR; Rapoport, AM; Sheftell, FD, 1999
)
3.19
"Rizatriptan wafer is a 5HT1B/1D agonist for use in the acute treatment of migraine. "( Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine.
Klapper, JA; O'Connor, S, 2000
)
3.19
"Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine."( The use of rizatriptan in the treatment of acute, multiple migraine attacks.
Saper, JR, 2000
)
1.42
"Rizatriptan is a selective 5-HT1B/1D receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. "( Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.
Block, GA; Getson, A; Goldstein, J; Jiang, K; Lines, C; Norman, B; Ryan, R,
)
1.88
"Rizatriptan is a potent, oral, 5-HT1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan. "( Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.
Block, GA; Giacovazzo, M; Malbecq, W; Paz, J; Reines, SA; Rodriguez, F; Teall, J; Tfelt-Hansen, P; Visser, WH,
)
2.09
"Rizatriptan is a novel, selective 5-HT1B/1D receptor agonist with a rapid onset of action after oral dosing for the acute treatment of migraine. "( Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups.
Block, GA; Goldstein, J; Polis, A; Reines, SA; Smith, ME,
)
1.88
"Rizatriptan is a selective 5-HT1B/1D receptor agonist for the acute treatment of migraine. "( Long-term efficacy and tolerability of rizatriptan wafers in migraine.
Ahrens, S; Cady, R; Crawford, G; Getson, A; Hairwassers, D; Lines, C; Visser, WH, 2001
)
2.02
"Rizatriptan is a potent, oral 5-HT(1B/1D) agonist with a rapid onset of action being investigated for the acute treatment of migraine. "( Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
Birk, KL; De Puy, ME; Fisher, A; Goldberg, MR; Lowry, RC; Musson, DG; Shadle, CR, 1999
)
1.98
"Rizatriptan ODT is an orally disintegrating formulation of rizatriptan, a selective 5-HT1B/1D receptor agonist."( Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine.
Bohidar, N; Boyle, D; Brandes, JL; Guerra, F; Johnson-Pratt, L; Kolodny, A; Loder, E; Santanello, N; Silberstein, S; Skobieranda, F; Wang, L, 2001
)
1.34
"Rizatriptan is a serotonin 5-HT1B/1D receptor agonist for acute treatment of migraine. "( Pharmacokinetics of rizatriptan in healthy elderly subjects.
Birk, KL; Gagliano, KD; Goldberg, MR; Musson, DG; Panebianco, DL; Rogers, JD, 2001
)
2.08
"Rizatriptan is a potent, selective 5-HT1B/1D receptor agonist shown to be fast, effective and well tolerated in the acute treatment of migraine."( Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.
Gerth, WC; Mannix, LK; McCarroll, KA; Santanello, NC; Vandormael, K; Zhang, Q, 2001
)
1.33
"Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes. "( Rizatriptan: an update of its use in the management of migraine.
Plosker, GL; Wellington, K, 2002
)
3.2
"Rizatriptan is an effective drug for the acute treatment of moderate or severe migraine. "( Rizatriptan: an update of its use in the management of migraine.
Plosker, GL; Wellington, K, 2002
)
3.2
"Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. "( Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
Barbosa, JS; Krymchantowski, AV, 2002
)
3.2

Effects

Rizatriptan has shown the quickest onset of action, both in controlled studies and in the different metaanalyses. The drug has a favorable side effect profile, and, provided contraindications are observed, severe adverse cardiovascular complications are extremely unlikely.

ExcerptReferenceRelevance
"Rizatriptan has a favorable side effect profile, and, provided contraindications are observed, severe adverse cardiovascular complications are extremely unlikely."( Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes.
Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V, 2001
)
1.32
"Rizatriptan has shown the quickest onset of action, both in controlled studies and in the different metaanalyses, which translates in high efficacy levels at two hours."( [Rizatriptan: experience after 15 years of clinical use].
Alvarez-Escudero, R; Pascual, J; Ramón-Carbajo, C, 2013
)
2.02
"Rizatriptan 10 mg has demonstrated, in a head-to-head study, higher response rates and a more rapid onset of action than sumatriptan 100 mg, together with a favorable tolerability profile."( Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis.
Göbel, H, 2010
)
1.37
"Rizatriptan has shown efficacy as an anti-migraine agent in clinical trials."( 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519.
Boulanger, CM; Desta, B; Hill, RG; Longmore, J; Schofield, WN; Taylor, AA, 1996
)
1.22
"Rizatriptan therefore has central activity which may contribute to its efficacy against migraine headache."( Rizatriptan has central antinociceptive effects against durally evoked responses.
Cumberbatch, MJ; Hargreaves, RJ; Hill, RG, 1997
)
2.46
"Rizatriptan has a favorable side effect profile, and, provided contraindications are observed, severe adverse cardiovascular complications are extremely unlikely."( Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes.
Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V, 2001
)
1.32

Actions

ExcerptReferenceRelevance
"Rizatriptan led to an increase of CNV amplitude that depended on the level of difficulty of the task."( Effects of rizatriptan on the contingent negative variation in healthy women.
Kotchoubey, B; Larbig, W; Strehl, U; Zank, R, 2008
)
1.46

Treatment

ExcerptReferenceRelevance
"Treatment with rizatriptan significantly slowed down neural tube development. "( Does the Anti-Migraine Drug Rizatriptan Affect Early Neural Tube Development in Chick Embryos?
Gurgen, GS; Guvenc, G; Sayin, M; Sayin, SS; Yuceer, N, 2019
)
1.16

Toxicity

ExcerptReferenceRelevance
" The most common dose-related adverse events were nausea, somnolence, and asthenia/fatigue."( Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups.
Block, GA; Goldstein, J; Polis, A; Reines, SA; Smith, ME,
)
0.44
"Rizatriptan was generally safe and well tolerated in the long-term acute treatment of migraine in pediatric patients aged 12-17 years and demonstrated a consistent treatment effect over time."( Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.
Assaid, C; Bachman, R; Ceesay, P; Connor, KM; Dupre, N; Hämäläinen, M; Harper Mozley, L; Hewitt, DJ; Ho, TW; Lewis, D; Lines, C; Mahoney, E; Michelson, D; Pearlman, E; Strickler, N, 2013
)
2.11

Pharmacokinetics

The pharmacokinetic parameters of two oral formulations of rizatriptan (CAS 144034-80-0) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions. The terminal half-life for frovatriptans was longer than riz atriptan. This study examined the pharmacokinetics and clinical interaction.

ExcerptReferenceRelevance
" The present studies investigated the potential for pharmacokinetic or pharmacodynamic interaction between beta-adrenoceptor blockers and rizatriptan."( Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.
De Smet, M; Goldberg, MR; Halpin, R; James, I; Kari, PH; Lee, Y; Lowry, R; Olah, TV; Sciberras, D; Tomasko, L; Vyas, KP; Zhao, J, 2001
)
0.75
"5 days) increased the AUC(0, infinity) for rizatriptan by approximately 67% and the Cmax by approximately 75%."( Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.
De Smet, M; Goldberg, MR; Halpin, R; James, I; Kari, PH; Lee, Y; Lowry, R; Olah, TV; Sciberras, D; Tomasko, L; Vyas, KP; Zhao, J, 2001
)
0.81
" The pharmacokinetic data (AUC(0-infinity) and Cmax) for the elderly in this study were compared with historical data from previous studies for healthy young adults (n = 65)."( Pharmacokinetics of rizatriptan in healthy elderly subjects.
Birk, KL; Gagliano, KD; Goldberg, MR; Musson, DG; Panebianco, DL; Rogers, JD, 2001
)
0.63
"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77."( Pharmacokinetics of rizatriptan in healthy elderly subjects.
Birk, KL; Gagliano, KD; Goldberg, MR; Musson, DG; Panebianco, DL; Rogers, JD, 2001
)
0.63
" There was no statistically significant difference for AUC or Cmax values between the nasal spray and the oral tablet."( Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans.
Chen, J; Gao, XL; Jiang, WM; Jiang, XG; Mei, N, 2005
)
0.63
" This quantitation method was successfully applied to the evaluation of the pharmacokinetic profiles of rizatriptan after single oral administration of 5, 10 and 15 mg rizatriptan tablets to 10 healthy volunteers (five males and five females)."( Determination of rizatriptan in human plasma by liquid chromatographic-eletrospray tandem mass spectrometry: application to a pharmacokinetic study.
Gao, HZ; Guo, JF; Liu, ZY; Qiao, SY; Sun, XH; Zhang, AJ; Zhao, L; Zhao, YM, 2006
)
0.89
"The pharmacokinetic parameters of two oral formulations of rizatriptan (CAS 144034-80-0, a capsule preparation as test and rizatriptan tablet as reference), given at a single dose of 10 mg each, were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions."( Evaluation of the bioequivalence and pharmacokinetics of two formulations of rizatriptan after single oral administration in healthy volunteers.
Chen, J; Jiang, WM; Jin, L; Liang, XG; Mei, N; Xie, YL, 2005
)
0.8
" Future studies are needed to determine whether this pharmacokinetic difference produces differential efficacy in a clinical setting."( Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study.
Alcorn, H; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Swan, SK; Woll, S, 2006
)
0.63
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To evaluate the pharmacokinetic profile and tolerability of single doses of rizatriptan oral disintegrating tablets (ODTs) in pediatric migraineurs."( Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012
)
0.88
" Pharmacokinetic data were compared with historical data on rizatriptan ODT 10mg in healthy adults."( Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012
)
0.89
" Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available."( Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Egan, CG; Mogavero, S; Savi, L, 2014
)
0.64
"3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29."( Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Egan, CG; Mogavero, S; Savi, L, 2014
)
0.88
"The pharmacokinetic analysis population included 40 volunteers, the safety analysis population included 40 volunteers."( [Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt].
Khokhlov, AL; Leykin, ZN, 2023
)
0.91
"The ratio of geometric means for the key pharmacokinetic parameters (AUC0-t, AUC0-inf and Cmax) of rizatriptan is close to 90%, CI is within the acceptable range for bioequivalent drugs (80-125%)."( [Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt].
Khokhlov, AL; Leykin, ZN, 2023
)
1.13

Compound-Compound Interactions

Horizontal penetration needling combined with rizatriptan monobenzoate tablets have significant therapeutic effect on rapid analgesia and continuous analgesia for migraine without aura in acute stage. Its effect is superior to simple horizontal penetration needled and simple riz atriptan Monobenzate tablets.

ExcerptReferenceRelevance
" Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice."( Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
Barbosa, JS; Krymchantowski, AV, 2002
)
1.76
"To observe the therapeutic effect of horizontal penetration needling combined with rizatriptan monobenzoate tablets, simple horizontal penetration needling and simple rizatriptan monobenzoate tablets for migraine without aura in acute stage."( [Clinical observation on horizontal penetration needling combined with rizatriptan monobenzoate tablets for migraine without aura in acute stage].
Fan, GQ; Hou, T; Kou, RZ; Lin, Q; Tao, LM; Wang, L; Yang, F; Yu, XL, 2021
)
1.08
" In the acupuncture plus medication group, treatment of acupuncture combined with rizatriptan monobenzoate tablets were given, the application was the same as the acupuncture group and the western medication group."( [Clinical observation on horizontal penetration needling combined with rizatriptan monobenzoate tablets for migraine without aura in acute stage].
Fan, GQ; Hou, T; Kou, RZ; Lin, Q; Tao, LM; Wang, L; Yang, F; Yu, XL, 2021
)
1.08
"Horizontal penetration needling combined with rizatriptan monobenzoate tablets have significant therapeutic effect on rapid analgesia and continuous analgesia for migraine without aura in acute stage, its effect is superior to simple horizontal penetration needling and simple rizatriptan monobenzoate tablets."( [Clinical observation on horizontal penetration needling combined with rizatriptan monobenzoate tablets for migraine without aura in acute stage].
Fan, GQ; Hou, T; Kou, RZ; Lin, Q; Tao, LM; Wang, L; Yang, F; Yu, XL, 2021
)
1.11

Bioavailability

Rizatriptan is a potent, oral, 5-HT1B/1D agonist. It has more rapid absorption and higher bioavailability than oral sumatripta. In early clinical trials, it was shown to have good bioavailability and favorable effects on quality of life.

ExcerptReferenceRelevance
" The objective of this work was to identify potent and selective 5-HT1D receptor agonists with high oral bioavailability and low central nervous system penetration."( Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
Baker, R; Beer, MS; Davey, WB; Guiblin, AR; Jelley, RA; Reeve, AJ; Routledge, H; Sternfeld, F; Street, LJ; Watt, AP, 1995
)
0.29
" The overall bioavailability (F ) of rizatriptan was approximately 40% in males."( Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.
Conroy, JA; De Smet, M; Keymeulen, B; Lee, Y; McLoughlin, DA; Mendel, CM; Olah, TV; Rogers, JD; Somers, G; Stepanavage, ME, 1999
)
0.84
" The absorption of rizatriptan was approximately 90%, but it experienced a moderate first-pass effect, resulting in a bioavailability estimate of 47%."( Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.
Chavez-Eng, C; Cheng, H; Ellis, JD; Geer, LA; Guiblin, AR; Halpin, RA; Liu, L; Matuszewski, BK; Rogers, JD; Varga, SL; Vyas, KP, 2000
)
0.88
" In early clinical trials, rizatriptan was shown to have good bioavailability and favorable effects on quality of life."( Rizatriptan versus usual care in long-term treatment of migraine.
Silberstein, SD, 2000
)
2.05
"Rizatriptan is a potent, oral, 5-HT1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan."( Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.
Block, GA; Giacovazzo, M; Malbecq, W; Paz, J; Reines, SA; Rodriguez, F; Teall, J; Tfelt-Hansen, P; Visser, WH,
)
2.09
"5 h) and rizatriptan has greater bioavailability than sumatriptan (45% versus 15%)."( Rizatriptan: pharmacological differences from sumatriptan and clinical results.
Lines, CR; McCarroll, KA; Visser, WH, 2001
)
2.17
" These advantages may reflect its improved pharmacological profile over sumatriptan in terms of higher oral bioavailability and a shorter time to maximum concentration."( A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine.
Pascual, J, 2004
)
0.7
" Bioavailability was estimated to be about 45%."( [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance].
Aijima, H; Ikemoto, F; Natsumeda, Y; Toru, T, 2004
)
1.23
" The relative bioavailability of nasal formulation to oral formulation was 96%+/-16%."( Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans.
Chen, J; Gao, XL; Jiang, WM; Jiang, XG; Mei, N, 2005
)
0.63
" ODTc showed a slightly, but not significantly, faster rate of absorption compared with tablet."( Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study.
Alcorn, H; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Swan, SK; Woll, S, 2006
)
0.63
"0mg/kg) to the rats, the absolute bioavailability was found to be 91."( Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats.
Guo, Y; Liao, YH; Liu, CY; Quan, LH; Wang, C, 2007
)
0.63
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Rizatriptan is a novel, selective 5-HT1B/1D receptor agonist with a rapid onset of action after oral dosing. The findings of this study indicate that there is little potential for dosages as high as 30 mg/day, the maximum recommended dosing schedule, to alter plasma concentrations of oral contraceptives.

ExcerptRelevanceReference
"The proportion of patients whose conditions improved from severe or moderate headache immediately before dosing to mild or no headache at 2 hours after drug administration (ie, headache relief)."( Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Ferrari, MD; Jiang, K; Lines, CR; Reines, SA; Terwindt, GM; Visser, WH, 1996
)
1.74
"7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462."( Pharmacokinetics and food interaction of MK-462 in healthy males.
Cerchio, KA; Cheng, H; Christie, K; James, I; McLoughlin, D; Olah, TV; Polvino, WJ; Rogers, JD; Sciberras, D; Yogendran, L, 1996
)
0.29
" On experiencing moderate or severe migraine headaches, patients rated headache severity prior to dosing and at 30-minute intervals for 2 hours after dosing."( Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
Block, G; Cutler, N; Gross, M; Jiang, K; Reines, S; Smith, B; Teall, J; Tuchman, M; Willoughby, E, 1998
)
1.74
" Rizatriptan wafer is a novel, freeze-dried dosage formulation of rizatriptan which rapidly disintegrates on the tongue, is swallowed with saliva, and may be taken without liquids."( Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.
Ahrens, SP; Block, GA; Farmer, MV; Jiang, K; Visser, WH; Williams, DL; Willoughby, E, 1999
)
1.52
" The findings of this study indicate that there is little potential for dosages as high as 30 mg/day, the maximum recommended dosing schedule, of rizatriptan to alter the plasma concentrations of oral contraceptives."( A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers.
Goldberg, MR; Liu, G; Shadle, CR, 2000
)
0.74
" In all women, rizatriptan was as effective in treating menstrual as well as nonmenstrual migraine: 68% of 139 patients taking rizatriptan 10 mg with a menstrually associated migraine had pain relief at 2 hours after dosing compared with 69% of 393 patients with nonmenstrually associated attacks (test of menstrual association = nonsignificant; the analysis had 80% power to detect a difference of six percentage points between groups)."( Rizatriptan in the treatment of menstrual migraine.
Johnson-Pratt, L; Le Jeunne, C; Lines, CR; Massiou, H; McCarroll, KA; Silberstein, SD, 2000
)
2.1
" Headache severity, functional disability, and associated migraine symptoms were measured immediately before dosing and at regular intervals up to 4 hours after the dose."( Within-patient consistency of response of rizatriptan for treating migraine.
Dahlöf, CG; Ferrari, MD; Kramer, MS; Lines, CR; Lipton, RB; McCarroll, KA, 2000
)
0.57
"Of the evaluable patients who treated three migraine attacks with 10 mg of rizatriptan (with an additional interspersed placebo-treated attack in most patients), 216 of 252 (86%) had pain relief (reduction of pain to mild or none), 122 of 252 (48%) were pain free, 211 of 250 (84%) had no nausea, 163 of 251 (65%) had no photophobia, 182 of 252 (72%) had no phonophobia, 136 of 249 (55%) had no functional disability, and 233 of 252 (92%) had no need for escape medications at 2 hours after dosing in at least two of three attacks."( Within-patient consistency of response of rizatriptan for treating migraine.
Dahlöf, CG; Ferrari, MD; Kramer, MS; Lines, CR; Lipton, RB; McCarroll, KA, 2000
)
0.8
" For each attack, patients rated headache severity, presence of associated symptoms, and functional disability prior to dosing and at intervals through 4 hours thereafter."( Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.
Block, GA; Getson, A; Goldstein, J; Jiang, K; Lines, C; Norman, B; Ryan, R,
)
0.44
"Rizatriptan is a novel, selective 5-HT1B/1D receptor agonist with a rapid onset of action after oral dosing for the acute treatment of migraine."( Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups.
Block, GA; Goldstein, J; Polis, A; Reines, SA; Smith, ME,
)
1.88
"In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan."( Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002
)
0.79
" For example, using the -3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks."( Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data.
Lines, CR; Massiou, H; McCarroll, KA; Silberstein, SD, 2002
)
0.63
"To determine the cost-effectiveness of the triptans, a meta-analysis was conducted of the efficacy data from 27 oral triptan trials, using the endpoint of "pain-free" status within 2 hours after initial dosing as the indicator of efficacy."( Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours.
Adelman, JU; Belsey, J,
)
0.13
" A secondary end point was to compare the time of occurrence of the maximum rizatriptan plasma concentration (t(max)) of each dosing method."( Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study.
Alcorn, H; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Swan, SK; Woll, S, 2006
)
0.86
" Seven 5-HT(1B/D) agonists have been approved in Germany with more than 20 dosage forms."( Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany.
Diener, HC; Katsarava, Z; Krobot, KJ; Liedert, B; Limmroth, V; Yoon, MS, 2006
)
0.55
"This was a retrospective cohort study conducted in a managed care organization for patients aged 18 years or older who had picked up at least one outpatient prescription for any sumatriptan dosage form at the pharmacy between January 2002 and June 2002."( Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Billups, SJ; Carroll, N; Delate, T; Gershovich, OE; Hoffman, CK, 2006
)
0.55
" End points included time to pain freedom (length of time from dosing to no pain) and time to onset of pain relief (mean time to onset of pain relief and proportion of patients reporting onset of pain relief at 30 minutes), satisfaction with treatment, and medication preference."( Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Barlas, S; Bell, CF; Foley, KA; Hu, XH; Solomon, G, 2006
)
0.59
"003), with significant differences noted as early as 15 minutes after dosing (P<0."( Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Barlas, S; Bell, CF; Foley, KA; Hu, XH; Solomon, G, 2006
)
0.59
"Significantly, more patients taking rizatriptan achieved both PR and PF within 2 h after dosing than other oral triptans."( Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
Chen, Y; Hu, XH; Ma, L; Ng-Mak, DS; Solomon, G, 2007
)
0.88
" Significantly more patients taking rizatriptan achieved onset of PR within 2 hours after dosing than those taking almotriptan (88."( Migraine treatment with rizatriptan and almotriptan: a crossover study.
Bigal, M; Hu, XH; Ng-Mak, DS, 2009
)
0.93
"In the treatment of acute migraine, patients need a drug that provides convenient dosing and consistent effectiveness."( Rizatriptan. Convenience and consistency.
Evans, RW, 2000
)
1.75
"In pediatric migraineurs, a weight-based dosing scheme generated plasma rizatriptan AUC((0-∞)) and C(max) values that were generally similar to those historically observed in adults administered a 10-mg dose of rizatriptan ODT (a proven effective dose)."( Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012
)
0.88
" The trial included a double-blind run-in with weight-based rizatriptan dosing (5 mg for < 40 kg, 10 mg for ≥ 40 kg)."( Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
Assaid, C; Bachman, R; Connor, K; Hämäläinen, M; Hewitt, DJ; Ho, TW; Lewis, D; Lines, C; Mahoney, E; Michelson, D; Mozley, LH; Pearlman, E; Strickler, N; Zhang, Y, 2012
)
0.91
" For preventive migraine treatment, the Childhood and Adolescent Migraine Prevention trial demonstrated that approximately 60% of children and adolescents with migraine will improve with a three-pronged treatment approach that includes: (1) lifestyle management counseling (on sleep, exercise, hydration, caffeine, and avoidance of meal skipping); (2) optimally dosed acute therapy, specifically nonsteroidal anti-inflammatory drugs and triptans; and (3) a preventive treatment that has some evidence for efficacy."( Pediatric and Adolescent Headache.
Gelfand, AA, 2018
)
0.48
" The uniformity of the dosage units, disintegration behavior and dissolution patterns of the ODFs were also evaluated prior to the pharmacokinetic study."( Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate.
Bera, H; Chen, Y; Cun, D; Guo, X; Rantanen, J; Song, Q; Tian, X; Wan, F; Yang, M, 2020
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
vasoconstrictor agentDrug used to cause constriction of the blood vessels.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tryptaminesTryptamine and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.62280.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)IC50 (µMol)10.00000.00042.08059.0000AID5998
5-hydroxytryptamine receptor 3BHomo sapiens (human)IC50 (µMol)10.00000.00041.95059.0000AID5998
5-hydroxytryptamine receptor 1AHomo sapiens (human)IC50 (µMol)0.35720.00010.666410.0000AID3913; AID3977
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.21650.00010.532610.0000AID3850; AID3860
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)6.30960.00040.908610.0000AID5701
5-hydroxytryptamine receptor 3AMus musculus (house mouse)IC50 (µMol)10.00001.41251.41251.4125AID5998
5-hydroxytryptamine receptor 1DHomo sapiens (human)IC50 (µMol)0.04520.00050.28702.4000AID4596; AID4641
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.01930.00010.808710.0000AID4627; AID4908; AID4934
5-hydroxytryptamine receptor 1BHomo sapiens (human)IC50 (µMol)0.04100.00050.39756.5000AID4511
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki0.01010.00010.54859.2100AID4256
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)7.94330.00010.88018.8500AID5405
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)8.97160.00011.03029.0000AID5637; AID5692
Alpha-1A adrenergic receptorHomo sapiens (human)IC50 (µMol)10.00000.00020.56145.4000AID5637
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)3.98110.00021.13514.6000AID5936
5-hydroxytryptamine receptor 3AHomo sapiens (human)IC50 (µMol)10.00000.00011.07899.0000AID5998
5-hydroxytryptamine receptor 1DSus scrofa (pig)IC50 (µMol)0.05010.00030.64963.7153AID4859
5-hydroxytryptamine receptor 3DHomo sapiens (human)IC50 (µMol)10.00000.00042.08059.0000AID5998
5-hydroxytryptamine receptor 3CHomo sapiens (human)IC50 (µMol)10.00000.00042.08059.0000AID5998
5-hydroxytryptamine receptor 3BMus musculus (house mouse)IC50 (µMol)10.00001.41251.41251.4125AID5998
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)3.98110.00041.17424.6000AID5936
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1DHomo sapiens (human)EC50 (µMol)0.00570.00080.00600.0160AID4571; AID4581
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (114)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
oligodendrocyte differentiationUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
chemokine-mediated signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemokine receptor activityUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
receptor serine/threonine kinase bindingUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
G protein-coupled receptor activityUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membraneUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
plasma membraneUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F2005Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)2005Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID3860Binding affinity for cloned human 5-hydroxytryptamine 1A receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID409602Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID3850In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4581Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1180706Antimigraine activity in migraine patient assessed as induction pain relief at 10 mg after 2 hrs2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID165752The compound was tested for functional activity by measuring the contraction of saphenous vein from New Zealand white rabbit1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4571Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID229102Percent efficacy relative to 5-HT1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID5637Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID5998Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID1864507Substrate activity at OCT1 (unknown origin) assessed as uptake ratio2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864506Substrate activity at human OCT2 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID4641Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID234876Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID5701Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID232943Binding selectivity for 5-HT 1D/1B receptors1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID3977Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID4591Intrinsic activity for 5-hydroxytryptamine 1D receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1180726Antimigraine activity in migraine patient assessed as pain relief incidence at 10 mg after 2 hrs (Rvb = 46.3%)2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID19418Partition coefficient (logD7.4)1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1180724Antimigraine activity in migraine patient assessed as pain freedom incidence at 10 mg after 2 hrs (Rvb = 14.3%)2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1180710Toxicity in migraine patient assessed as incidence of drug-related adverse events at 10 mg2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID4596Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID5405Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID165754Functional activity was determined by the contraction of New Zealand white rabbit saphenous vein.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID165751Maximum vein contraction obtained relative to 5-hydroxytryptamine1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID5936Binding activity radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID5692Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID4908Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID4627In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID3913Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID4511Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4859Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1385404Antagonist activity at human GPR17 expressed in human 1321N1 cells assessed as inhibition of MDL 29,951-induced calcium mobilization at >30 nM after 1 hr by Oregon Green BAPTA-1/AM dye-based fluorescence assay relative to control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864493Substrate activity at human OCT3 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1385400Agonist activity at human GPR17 expressed in human 1321N1 cells assessed as induction of calcium mobilization at >30 uM after 1 hr by Oregon Green BAPTA-1/AM dye-based fluorescence assay relative to control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4256In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID409603Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID1385398Antagonist activity at human GPR17 expressed in human 1321N1 cells assessed as inhibition of MDL 29,951-induced calcium mobilization after 1 hr by Oregon Green BAPTA-1/AM dye-based fluorescence assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID4934Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID227246Compound was administered 10 min prior to trigeminal stimulation and was evaluated for the decrease extravasation2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (333)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's40 (12.01)18.2507
2000's212 (63.66)29.6817
2010's68 (20.42)24.3611
2020's13 (3.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.26 (24.57)
Research Supply Index6.12 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index196.85 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (106.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials106 (30.37%)5.53%
Reviews71 (20.34%)6.00%
Case Studies14 (4.01%)4.05%
Observational0 (0.00%)0.25%
Other158 (45.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (32)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine [NCT04384367]Phase 31,664 participants (Anticipated)Interventional2022-12-30Recruiting
A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops [NCT01306266]0 participants (Actual)Interventional2011-02-28Withdrawn
A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine [NCT00897104]Phase 3933 participants (Actual)Interventional1995-08-31Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine [NCT00111722]Phase 3393 participants (Actual)Interventional2005-05-27Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT) [NCT00250458]Phase 3346 participants (Actual)Interventional2006-03-31Completed
A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild [NCT00095004]Phase 3167 participants (Actual)Interventional2004-10-21Completed
A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache [NCT00899379]Phase 3473 participants (Actual)Interventional1995-04-30Completed
A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine [NCT00898677]Phase 31,268 participants (Actual)Interventional1995-09-30Completed
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029) [NCT01286207]Phase 31,959 participants (Actual)Interventional1995-03-31Completed
A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild [NCT00092963]Phase 3529 participants (Actual)Interventional2004-08-17Completed
A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence [NCT00897949]Phase 31,473 participants (Actual)Interventional1995-03-31Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine [NCT00111709]Phase 3393 participants (Actual)Interventional2005-05-27Completed
An Observer-Blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine [NCT00397254]Phase 4197 participants (Actual)Interventional2006-12-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis [NCT00812006]Phase 3108 participants (Actual)Interventional2009-03-24Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years [NCT00604812]Phase 131 participants (Actual)Interventional2007-12-17Completed
A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan [NCT01086358]Phase 460 participants (Actual)Interventional2009-09-30Completed
A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura [NCT01004263]Phase 3674 participants (Actual)Interventional2009-12-01Completed
A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents [NCT01001234]Phase 31,382 participants (Actual)Interventional2009-11-30Completed
A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults [NCT04163185]Phase 3302 participants (Actual)Interventional2019-10-08Completed
MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults [NCT03896009]Phase 31,594 participants (Actual)Interventional2019-03-04Completed
A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. [NCT00753311]Phase 480 participants (Actual)Interventional2009-07-31Completed
An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor [NCT05550207]Phase 3100 participants (Anticipated)Interventional2022-08-31Recruiting
A Multicenter, Double-Blind, Placebo and Active-Controlled, Dose-Finding Study of MK0974 in the Treatment of Acute Migraine [NCT00246337]Phase 2420 participants (Actual)Interventional2005-11-30Completed
Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs [NCT00360282]36 participants (Actual)Interventional2006-08-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine [NCT00516737]Phase 3207 participants (Actual)Interventional2007-10-03Completed
A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment [NCT01057160]Phase 4195 participants (Actual)Interventional2008-05-31Completed
A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura [NCT00443209]Phase 31,068 participants (Actual)Interventional2007-02-21Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders [NCT00894556]Phase 3109 participants (Actual)Interventional2009-06-10Completed
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache [NCT00471952]Phase 350 participants (Actual)Interventional2007-04-30Completed
A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine. [NCT00300924]Phase 3200 participants Interventional2006-03-31Completed
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache [NCT00719134]Phase 476 participants (Actual)Interventional2008-09-30Completed
A Phase II/III Trial on Rizatriptan for Vestibular Migraine [NCT02447991]Phase 2/Phase 3223 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00246337 (4) [back to overview]Pain Freedom at 2 Hours
NCT00246337 (4) [back to overview]Sustained Pain Freedom
NCT00246337 (4) [back to overview]Sustained Pain Relief
NCT00246337 (4) [back to overview]Pain Relief at 2 Hours
NCT00250458 (2) [back to overview]Participants With Elimination of Nausea at 2 Hours Postdose
NCT00250458 (2) [back to overview]Participants With Pain Relief at 2 Hours Postdose
NCT00360282 (2) [back to overview]Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus
NCT00360282 (2) [back to overview]Change From Baseline in Motion Sickness to Post Vestibular Stimulus
NCT00397254 (8) [back to overview]Number of Migraine Attacks
NCT00397254 (8) [back to overview]Number of Days With Migraine
NCT00397254 (8) [back to overview]Average Attack Duration
NCT00397254 (8) [back to overview]Adverse Experiences
NCT00397254 (8) [back to overview]Headache Severity of All Attacks
NCT00397254 (8) [back to overview]Percentage of Attacks With Return to Normal Ability to Perform Activities at 2 Hours Post-dose
NCT00397254 (8) [back to overview]Percentage of Attacks With Symptom Elimination at 2 Hours
NCT00397254 (8) [back to overview]Percentage of Responders
NCT00443209 (5) [back to overview]Percentage of Participant Migraine Attacks With Pain Freedom (PF) at 2 Hours Post-Dose
NCT00443209 (5) [back to overview]Percentage of Participants With At Least One Vital Sign Measurement Outside Predefined Limits of Change
NCT00443209 (5) [back to overview]Percentage of Participants With At Least One Triptan-Related Adverse Experience (AE)
NCT00443209 (5) [back to overview]Percentage of Participants With At Least One Laboratory AE
NCT00443209 (5) [back to overview]Percentage of Participants With At Least One Clinical AE
NCT00516737 (7) [back to overview]Number of Participants With 24-Hour Sustained Pain Freedom
NCT00516737 (7) [back to overview]Number of Participants Who Are Pain Free at 2 Hours Post-Dose
NCT00516737 (7) [back to overview]Number of Participants With no Rescue Use up to 24 Hours Post-Dose
NCT00516737 (7) [back to overview]Number of Participants With Absence of Photophobia at 2 Hours Post-dose
NCT00516737 (7) [back to overview]Number of Participants With Absence of Phonophobia at 2 Hours Post-dose
NCT00516737 (7) [back to overview]Number of Participants With Absence of Nausea at 2 Hours Post-dose
NCT00516737 (7) [back to overview]Number of Participants With Absence of Functional Disability at 2 Hours Post-Dose
NCT00604812 (5) [back to overview]Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Maximum Concentration (Cmax)
NCT00604812 (5) [back to overview]Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Apparent Half-life (Apparent t½)
NCT00604812 (5) [back to overview]Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Time to Maximum Concentration (Tmax)
NCT00604812 (5) [back to overview]Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan- Area Under the Curve (AUC(0-∞))
NCT00604812 (5) [back to overview]Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs
NCT00719134 (2) [back to overview]Pain Free at 2 Hours After Treatment
NCT00719134 (2) [back to overview]Change in Headache Intensity
NCT00812006 (5) [back to overview]Pain Freedom (PF)
NCT00812006 (5) [back to overview]Sustained Pain Relief (SPR)
NCT00812006 (5) [back to overview]Treatment Satisfaction (TS)
NCT00812006 (5) [back to overview]Pain Relief (PR)
NCT00812006 (5) [back to overview]Normal Rating of Functional Disability (NRFD)
NCT00894556 (2) [back to overview]Pain Relief (PR)
NCT00894556 (2) [back to overview]Pain Freedom (PF)
NCT00897104 (7) [back to overview]Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment
NCT00897104 (7) [back to overview]Participants Who Used Escape Medication 2 Hours After the Treatment Dose
NCT00897104 (7) [back to overview]Pain Relief at 2 Hours After Treatment
NCT00897104 (7) [back to overview]Pain Free at 2 Hours After Treatment
NCT00897104 (7) [back to overview]Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])
NCT00897104 (7) [back to overview]Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities
NCT00897104 (7) [back to overview]Time to Relief Within 2 Hours After Treatment
NCT00897949 (5) [back to overview]Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug
NCT00897949 (5) [back to overview]Pain Free at 2 Hours After the Initial Dose of Test Drug
NCT00897949 (5) [back to overview]No Disability at 2 Hours After the Initial Dose of Test Drug
NCT00897949 (5) [back to overview]Pain Relief 2 Hours After Treatment for Headache Recurrence
NCT00897949 (5) [back to overview]Pain Relief at 2 Hours After the Initial Dose of Test Drug
NCT00898677 (5) [back to overview]Time to Relief Within 2 Hours After Dose
NCT00898677 (5) [back to overview]Pain Relief at 2 Hours After Dose
NCT00898677 (5) [back to overview]Pain Free at 2 Hours After Dose
NCT00898677 (5) [back to overview]Nausea at 2 Hours After Dose
NCT00898677 (5) [back to overview]Functional Status at 2 Hours After Dose
NCT00899379 (4) [back to overview]Pain Relief at 2 Hours During the Second Migraine Attack Period
NCT00899379 (4) [back to overview]Pain Relief at 2 Hours During the Third Migraine Attack Period
NCT00899379 (4) [back to overview]Pain Relief at 2 Hours During the First Migraine Attack Period
NCT00899379 (4) [back to overview]Pain Relief at 2 Hours During the Fourth Migraine Attack Period
NCT01001234 (4) [back to overview]Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age
NCT01001234 (4) [back to overview]Pain Freedom at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age
NCT01001234 (4) [back to overview]Pain Relief at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age
NCT01001234 (4) [back to overview]Pain Relief at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age
NCT01004263 (5) [back to overview]Percentage of Participant's Migraine Attacks With Pain Freedom at 2 Hours Post Dose
NCT01004263 (5) [back to overview]Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post Dose
NCT01004263 (5) [back to overview]Number of Participants With AEs Within 14 Days Post Any Dose
NCT01004263 (5) [back to overview]Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose
NCT01004263 (5) [back to overview]Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post Dose
NCT01086358 (4) [back to overview]Favorable Response on Migraine-ACT
NCT01086358 (4) [back to overview]Workplace Productivity and Activity Impairment Scale (WPAI).
NCT01086358 (4) [back to overview]Lost Workplace Productivity
NCT01086358 (4) [back to overview]Lost Activity Time
NCT01286207 (5) [back to overview]Number of Participants With Drug-related Lab Adverse Experiences
NCT01286207 (5) [back to overview]Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug
NCT01286207 (5) [back to overview]Number of Participants Who Discontinued Due to Clinical Adverse Experiences
NCT01286207 (5) [back to overview]Number of Participants With Drug-related Clinical Adverse Experiences
NCT01286207 (5) [back to overview]Number of Participants With Serious Clinical Adverse Experiences
NCT02447991 (17) [back to overview]Episodes With Complete Relief of Unsteadiness/Dizziness Vestibular Symptoms
NCT02447991 (17) [back to overview]Episodes With Complete Relief of Vertigo as Vestibular Symptom
NCT02447991 (17) [back to overview]Episodes With Headache Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Episodes With Headache Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Nausea/Vomiting Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Episodes With Nausea/Vomiting Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Photophobia/Phonophobia Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Episodes With Photophobia/Phonophobia Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Sensitivity to Motion Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Episodes With Sensitivity to Motion Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Sustained Reduction in Severity of Dizziness/Unsteadiness From Moderate/Severe to None/Mild Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Sustained Reduction in Severity of Vertigo From Moderate/Severe to None/Mild Without Additional Medication
NCT02447991 (17) [back to overview]Episodes With Symptoms of Unsteadiness/Dizziness Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild
NCT02447991 (17) [back to overview]Health-Related Quality of Life
NCT02447991 (17) [back to overview]Satisfaction With Treatment
NCT02447991 (17) [back to overview]Side Effects
NCT03896009 (2) [back to overview]Percentage of Subjects With Absence of Most Bothersome Symptom
NCT03896009 (2) [back to overview]Percentage of Subjects Reporting Headache Pain Freedom

Pain Freedom at 2 Hours

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), 3 (severe). Pain freedom is defined as no pain (Grade 0) at 2 hours post dose. (NCT00246337)
Timeframe: 2 hours post dose

InterventionParticipants (Number)
Placebo16
MK0974 25 mg3
MK0974 50 mg7
MK0974 100 mg3
MK0974 200 mg2
MK0974 300 mg17
MK0974 400 mg11
MK0974 600 mg13
Rizatriptan 10 mg11

[back to top]

Sustained Pain Freedom

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), 3 (severe). Sustained pain freedom is defined as pain freedom at 2 hours and no headache return to mild/moderate/severe, no need for the optional 2nd dose, or any rescue medication, between 2 and 24 hours post dose. (NCT00246337)
Timeframe: 2-24 hours post dose

InterventionParticipants (Number)
Placebo12
MK0974 25 mg1
MK0974 50 mg7
MK0974 100 mg3
MK0974 200 mg1
MK0974 300 mg15
MK0974 400 mg10
MK0974 600 mg13
Rizatriptan 10 mg6

[back to top]

Sustained Pain Relief

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), 3 (severe). Sustained pain relief is defined as pain relief at 2 hours and no headache recurrence, no need for the optional 2nd dose, or any rescue medication, between 2 and 24 hours post dose. (NCT00246337)
Timeframe: 2-24 hours post dose

InterventionParticipants (Number)
Placebo27
MK0974 25 mg1
MK0974 50 mg9
MK0974 100 mg3
MK0974 200 mg3
MK0974 300 mg20
MK0974 400 mg17
MK0974 600 mg21
Rizatriptan 10 mg12

[back to top]

Pain Relief at 2 Hours

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), 3 (severe). Pain Relief is defined as participants reporting relief from moderate to severe migraine headache (Grade 2 or 3) to mild or none (Grade 1 or 0) in the setting of a typical migraine attack. (NCT00246337)
Timeframe: 2 hours post dose

InterventionParticipants (Number)
Placebo52
MK0974 25 mg5
MK0974 50 mg9
MK0974 100 mg8
MK0974 200 mg5
MK0974 300 mg25
MK0974 400 mg22
MK0974 600 mg27
Rizatriptan 10 mg24

[back to top]

Participants With Elimination of Nausea at 2 Hours Postdose

Participants reporting the absence of nausea at 2 hours post treatment. Absence or presence of nausea was recorded by the participants in an electronic diary. Absence is defined as no nausea at 2 hours post-treatment. (NCT00250458)
Timeframe: At 2 hours after treatment

,
InterventionParticipants (Number)
No Nausea at 2 HoursNausea at 2 Hours
Placebo5735
Rizatriptan 10 mg13055

[back to top]

Participants With Pain Relief at 2 Hours Postdose

Participants reporting pain relief defined as a reduction of pain severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment. (NCT00250458)
Timeframe: 2 hours after treatment

,
InterventionParticipants (Number)
2-Hour Pain ReliefNo 2-Hour Pain Relief
Placebo5042
Rizatriptan 10 mg12956

[back to top]

Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus

Subjective report of distress ranging from 0 to 10 based on the method of Wolpe. Zero indicates no distress and 10 indicates severe distress. Measures used in this analysis match the times used in the analysis for Outcome 1. (NCT00360282)
Timeframe: Pre and Post Stimulus (6 minutes apart)

Interventionunits on a scale (Median)
Rizatriptan Visit3
Placebo Visit2

[back to top]

Change From Baseline in Motion Sickness to Post Vestibular Stimulus

Scores are based on a scale developed by Graybiel which rates seven subjective and objective signs of motion sickness. The total scores ranged from from 0 to 25. Zero indicating no motion sickness. Greater than 16 indicates severe motion sickness. Trials were stopped if scores were 16 or greater. Scores were taken before and after each rotation. (NCT00360282)
Timeframe: Pre and Post Stimulus (about 6 minutes apart)

Interventionunits on a scale (Median)
Rizatriptan Visit5.1
Placebo Visit9

[back to top]

Number of Migraine Attacks

(NCT00397254)
Timeframe: 6 months

InterventionMigraine attacks (Mean)
Rizatriptan 27 Tablets - Clinical Limit4.855
Rizatriptan 9 Tablets - Formulary Limit4.399

[back to top]

Number of Days With Migraine

(NCT00397254)
Timeframe: 6 months

InterventionDays (Mean)
Rizatriptan 27 Tablets - Clinical Limit2.666
Rizatriptan 9 Tablets - Formulary Limit2.738

[back to top]

Average Attack Duration

(NCT00397254)
Timeframe: 6 months

InterventionHours (Mean)
Rizatriptan 27 Tablets - Clinical Limit11.569
Rizatriptan 9 Tablets - Formulary Limit12.930

[back to top]

Adverse Experiences

Participants with one or more Adverse Experiences (AEs) in Formulary Limit Group versus Clinical Limit Group collected from time patient provided informed consent until return at Visit 7 or through 14 days post-dosing of the last dose of study medication if serious adverse experience. Defined as any unfavorable and unintended change in structure, function, or chemistry of the body temporally associated with use of provided product whether or not considered related to use of the product. Includes any worsening of a preexisting condition temporally associated with use of provided product. (NCT00397254)
Timeframe: 6 months

InterventionParticipants (Number)
Rizatriptan 27 Tablets - Clinical Limit18
Rizatriptan 9 Tablets - Formulary Limit24

[back to top]

Headache Severity of All Attacks

4-Point Headache Severity Scale (0 = No Pain / 1 = Mild Pain / 2 = Moderate Pain / 3 = Severe Pain) (NCT00397254)
Timeframe: 6 months

InterventionUnits on a scale (Median)
Rizatriptan 27 Tablets - Clinical Limit1.50
Rizatriptan 9 Tablets - Formulary Limit1.59

[back to top]

Percentage of Attacks With Return to Normal Ability to Perform Activities at 2 Hours Post-dose

Percentage of attacks with mild, moderate or severely impaired ability to perform activities pre-treatment with return to normal function at 2 hours post-dose in Formulary Limit Group versus Clinical Limit Group (NCT00397254)
Timeframe: 6 months

InterventionPercentage of attacks (Number)
Rizatriptan 27 Tablets - Clinical Limit50.74
Rizatriptan 9 Tablets - Formulary Limit48.67

[back to top]

Percentage of Attacks With Symptom Elimination at 2 Hours

Percentage of attacks with elimination of all associated symptoms at 2 hours post-treatment in Formulary Limit Group versus percentage of attacks with elimination of all associated symptoms at 2 hours post-treatment in Clinical Limit Group (NCT00397254)
Timeframe: 6 months

InterventionPercentage of attacks (Number)
Rizatriptan 27 Tablets - Clinical Limit58.35
Rizatriptan 9 Tablets - Formulary Limit56.60

[back to top]

Percentage of Responders

Percentage of Responders (50% decrease in attack frequency) of Formulary Limit Group versus Percentage of Responders (50% decrease in attack frequency) in Clinical Limit Group (NCT00397254)
Timeframe: 6 months

InterventionPercentage of Participants (Number)
Rizatriptan 27 Tablets - Clinical Limit7.79
Rizatriptan 9 Tablets - Formulary Limit2.70

[back to top]

Percentage of Participant Migraine Attacks With Pain Freedom (PF) at 2 Hours Post-Dose

Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from mild, moderate or severe migraine headache (Grade 1, 2, or 3) at baseline to no pain (Grade 0) 2 hours post-dose. (NCT00443209)
Timeframe: 2 hours post-dose (Up to 18 months)

InterventionPercentage of Migraine Attacks (Mean)
Telcagepant 280 mg/300 mg38.9
Rizatriptan 10 mg47.5

[back to top]

Percentage of Participants With At Least One Vital Sign Measurement Outside Predefined Limits of Change

Predefined limits of change were established for vital sign measurements: Systolic Blood Pressure (>=180 mm Hg and 20 mm Hg increase OR <=90 mm Hg and 20 mm Hg decrease), Diastolic Blood Pressure (>=105 mm Hg and 15 mm Hg increase OR <=50 mm Hg and 15 mm Hg decrease), Pulse (>=120 beats per minute [bpm] and 15 bpm increase OR <=50 bpm and 15 bpm decrease), Body Temperature (>38º C [oral equivalent]) and Respiratory Rate (>25 or increase of 10 OR <5 or decrease of 10 [per minute]). Participants were monitored for vital sign measurements outside predefined limits of change for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)

,
InterventionPercentage of Participants (Number)
Systolic Blood Pressure IncreaseSystolic Blood Pressure DecreaseDiastolic Blood Pressure IncreaseDiastolic Blood Pressure DecreasePulse IncreasePulse DecreaseBody Temperature IncreaseRespiratory Rate Increase or Decrease
Rizatriptan 10 mg0.31.30.61.00.01.60.30.6
Telcagepant 280 mg/300 mg0.21.40.31.10.00.60.30.8

[back to top] [back to top]

Percentage of Participants With At Least One Laboratory AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants were monitored for laboratory AEs for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)

InterventionPercentage of Participants (Number)
Telcagepant 280 mg/300 mg1.9
Rizatriptan 10 mg1.6

[back to top]

Percentage of Participants With At Least One Clinical AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination. Participants were monitored for clinical AEs for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)

InterventionPercentage of Participants (Number)
Telcagepant 280 mg/300 mg58.7
Rizatriptan 10 mg63.9

[back to top]

Number of Participants With 24-Hour Sustained Pain Freedom

24-hour sustained pain freedom (defined as pain freedom from 2 to 24 hours post-dose and no use of rescue medication). Participants assessed pain severity and use of rescue medication on a paper diary. (NCT00516737)
Timeframe: 24 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT48
Placebo17

[back to top]

Number of Participants Who Are Pain Free at 2 Hours Post-Dose

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), or 3 (severe). Pain free = rating of 0 (no pain) at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT61
Placebo27

[back to top]

Number of Participants With no Rescue Use up to 24 Hours Post-Dose

Participants recorded use of any rescue medication up to 24 hours after dosing with study medication on a paper diary. (NCT00516737)
Timeframe: 24 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT61
Placebo32

[back to top]

Number of Participants With Absence of Photophobia at 2 Hours Post-dose

Absence or presence of photophobia was recorded by the participants on a paper diary. Absence is defined as no photophobia at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT69
Placebo43

[back to top]

Number of Participants With Absence of Phonophobia at 2 Hours Post-dose

Absence or presence of phonophobia was recorded by the participants on a paper diary. Absence is defined as no phonophobia at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT72
Placebo55

[back to top]

Number of Participants With Absence of Nausea at 2 Hours Post-dose

Absence or presence of nausea was recorded by the participants on a paper diary. Absence is defined as no nausea at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT82
Placebo73

[back to top]

Number of Participants With Absence of Functional Disability at 2 Hours Post-Dose

"Level of functional disability was assessed on a paper diary by the participants.~Level of functional disability was rated as: normal, mildly impaired, severely impaired or unable to do activities, requires bed rest. Absence of functional disability defined as a rating of normal at 2 hours post-dose." (NCT00516737)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Rizatriptan 10 mg ODT66
Placebo42

[back to top]

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Maximum Concentration (Cmax)

Preliminary pharmacokinetics data; Maximum concentration (Cmax); i.e, highest concentration of drug achieved (NCT00604812)
Timeframe: 24 Hours

Interventionng/mL (Mean)
Panel A Rizatriptan24.6
Panel B Rizatriptan25.0
Panel C Rizatriptan18.4

[back to top]

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Apparent Half-life (Apparent t½)

Preliminary pharmacokinetics data; Apparent half-life (t½) (NCT00604812)
Timeframe: 24 Hours

InterventionHours (Mean)
Panel A Rizatriptan1.3
Panel B Rizatriptan1.6
Panel C Rizatriptan1.6

[back to top]

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Time to Maximum Concentration (Tmax)

Preliminary pharmacokinetics data; Time to maximum concentration (Tmax); i.e., amount of time required to reach maximum concentration (NCT00604812)
Timeframe: 24 Hours

InterventionHours (Median)
Panel A Rizatriptan1.0
Panel B Rizatriptan1.5
Panel C Rizatriptan1.3

[back to top]

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan- Area Under the Curve (AUC(0-∞))

Preliminary pharmacokinetics data; Area Under the Curve (AUC(0-∞)); i.e., area under the concentration-time plot (NCT00604812)
Timeframe: 24 Hours

Interventionng hr/mL (Mean)
Panel A Rizatriptan59.4
Panel B Rizatriptan84.0
Panel C Rizatriptan67.93

[back to top]

Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs

All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram) and laboratory safety tests (hematology/blood chemistry/urinalysis) (NCT00604812)
Timeframe: 24 Hours

,,
InterventionParticipants (Number)
Serious Adverse EventsNon-Serious Adverse EventsNo Adverse Events Reported
Placebo034
Rizatriptan 10 mg077
Rizatriptan 5 mg037

[back to top]

Pain Free at 2 Hours After Treatment

A secondary measure of attack outcome was based on categorical classification of the pain freedom (pain score = 0) 2.5 hours after onset of headache. (NCT00719134)
Timeframe: 2 hours after treatment

Interventionpercent of patients pain free (Number)
pain free with maxaltpain free with placebo
All Participants25.56.6

[back to top]

Change in Headache Intensity

The primary outcome measure was the change in headache between the baseline pain score recorded 30 min after the onset of headache and the pain score recorded 2 hours later as measured on a visual analog scale ranging from 0 (no pain) to 10 (worst pain imaginable). (NCT00719134)
Timeframe: 2 hours after treatment

Interventionpercent change (Mean)
percent change with Maxaltpercent change with placebo
All Participants-47.6-20.7

[back to top]

Pain Freedom (PF)

Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00812006)
Timeframe: 2 hours post dose

,
InterventionAttacks (Number)
Resulting in PF 2 hours post doseNot resulting in PF 2 hours post dose
Placebo984
Rizatriptan74119

[back to top]

Sustained Pain Relief (SPR)

24-hour sustained pain relief (defined as pain relief at 2 hours post dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the respective period after dosing with the blinded study medication. (NCT00812006)
Timeframe: 2 - 24 hours post dose

,
InterventionAttacks (Number)
Resulting in SPR 2-24 hours post doseNot resulting in SPR 2-24 hours post dose
Placebo1281
Rizatriptan67126

[back to top]

Treatment Satisfaction (TS)

Patient satisfaction was assessed on a paper diary by the participants. Level of satisfaction was rated as: completely satisfied, very satisfied, somewhat satisfied, neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied. The overall 24-hour assessment of study medication was dichotomized to Satisfaction (completely satisfied, very satisfied, somewhat satisfied) and Non-satisfaction (neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied) for analysis. (NCT00812006)
Timeframe: 24 hours post dose

,
InterventionAttacks (Number)
Resulting in TS at 24 hours post doseNot resulting in TS at 24 hours post dose
Placebo3162
Rizatriptan11776

[back to top]

Pain Relief (PR)

Pain severity was rated by the participants in a paper diary. Pain severity rating scale : 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00812006)
Timeframe: 2 hours post dose

,
InterventionAttacks (Number)
Resulting in PR at 2 hours post doseNot resulting in PR at 2 hours post dose
Placebo2172
Rizatriptan10588

[back to top]

Normal Rating of Functional Disability (NRFD)

Level of functional disability was assessed on a paper diary by the participants. Level of functional disability was rated as: normal, mildly impaired, severely impaired, or unable to do activities, requires bedrest. Functional disability ratings was dichotomized to Normal and Not Normal (mildly impaired, severely impaired, or unable to do activities, requires bedrest) for analysis. (NCT00812006)
Timeframe: 2 hours post dose

,
InterventionAttacks (Number)
Resulting in NRFD at 2 hours post doseNot resulting in NRFD at 2 hours post dose
Placebo1677
Rizatriptan85108

[back to top]

Pain Relief (PR)

Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00894556)
Timeframe: 2 hours post dose

,
Interventionattacks (Number)
Resulting in PR at 2 hours post doseNot resulting in PR at 2 hours post dose
Placebo2178
Rizatriptan102100

[back to top]

Pain Freedom (PF)

Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00894556)
Timeframe: 2 hours post dose

,
Interventionattacks (Number)
Resulting in PF at 2 hours post doseNot resulting in PF at 2 hours post dose
Placebo1287
Rizatriptan46156

[back to top]

Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment

Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment. (NCT00897104)
Timeframe: 2 hours after treatment

,,
InterventionParticipants (Number)
2-hour PhotophobiaNo 2-hour Photophobia2-hour PhonophobiaNo 2-hour Phonophobia2-hour NauseaNo 2-hour NauseaNot Analyzed for Nausea2-hour VomitingNo 2-hour VomitingNot Analyzed for Vomiting
Placebo66144733483026677
Rizatriptan 5 mg1611891262241052432123308
Sumatriptan 5 mg15320112522913122121233012

[back to top]

Participants Who Used Escape Medication 2 Hours After the Treatment Dose

Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication. (NCT00897104)
Timeframe: 2 hours after treatment

,,
InterventionParticipants (Number)
Used Escape MedicationDid not Use Escape Medication
Placebo3347
Rizatriptan 5 mg73282
Sumatriptan 5 mg55302

[back to top]

Pain Relief at 2 Hours After Treatment

Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment (NCT00897104)
Timeframe: 2 hours after treatment

,,
InterventionParticipants (Number)
2-hour pain reliefNo 2-hour pain relief
Placebo1862
Rizatriptan 5 mg223129
Sumatriptan 5 mg238118

[back to top]

Pain Free at 2 Hours After Treatment

Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain). (NCT00897104)
Timeframe: 2 hours after treatment

,,
InterventionParticipants (Number)
2-hour pain freedomNo 2-hour pain freedom
Placebo278
Rizatriptan 5 mg95257
Sumatriptan 5 mg113243

[back to top]

Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])

Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence (NCT00897104)
Timeframe: 24 hours

InterventionHours (Mean)
Rizatriptan 5 mg11.07
Sumatriptan 5 mg11.58
Placebo14.38

[back to top]

Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities

Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest). (NCT00897104)
Timeframe: 2 hours after treatment

,,
InterventionParticipants (Number)
NormalMildly ImpairedSeverely ImpairedRequired Bed Rest
Placebo4281830
Rizatriptan 5 mg1081523852
Sumatriptan 5 mg1161484249

[back to top]

Time to Relief Within 2 Hours After Treatment

Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg). (NCT00897104)
Timeframe: within 2 hours after treatment

,,
InterventionParticipants (Number)
First pain relief within 2 hrsPain relief did not occur within 2 hrs
Placebo2456
Rizatriptan 5 mg231121
Sumatriptan 5 mg247109

[back to top]

Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug

(NCT00897949)
Timeframe: 2 hours after initial dose of test drug

,,
InterventionParticipants (Number)
Used escape medicationDid not use escape medication
Placebo128176
Rizatriptan 10 mg76380
Rizatriptan 5 mg101357

[back to top]

Pain Free at 2 Hours After the Initial Dose of Test Drug

Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

,,
InterventionParticipants (Number)
Reporting no painReporting pain
Placebo30272
Rizatriptan 10 mg193262
Rizatriptan 5 mg150307

[back to top]

No Disability at 2 Hours After the Initial Dose of Test Drug

Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

,,
InterventionParticipants (Number)
NormalMildly ImpairedSeverely ImpairedRequires Bedrest
Placebo541185375
Rizatriptan 10 mg2091484552
Rizatriptan 5 mg1751605666

[back to top]

Pain Relief 2 Hours After Treatment for Headache Recurrence

Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours). (NCT00897949)
Timeframe: 2 hours after treatment for recurrence

,,,,,
InterventionParticipants (Number)
Pain reliefNo pain relief
Placebo / Rizatriptan 10 mg184
Placebo / Rizatriptan 5 mg125
Rizatriptan 10 mg / Placebo3342
Rizatriptan 10 mg / Rizatriptan 10 mg5312
Rizatriptan 5 mg / Placebo3227
Rizatriptan 5 mg / Rizatriptan 5 mg3916

[back to top]

Pain Relief at 2 Hours After the Initial Dose of Test Drug

Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

,,
InterventionParticipants (Number)
Reporting pain reliefNot reporting pain relief
Placebo106196
Rizatriptan 10 mg322133
Rizatriptan 5 mg285172

[back to top]

Time to Relief Within 2 Hours After Dose

Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose (NCT00898677)
Timeframe: within 2 hours after dose

,,,
InterventionParticipants (Number)
First pain relief within 2 hrsPain relief did not occur within 2 hrs
Placebo7287
Rizatriptan 10 mg265120
Rizatriptan 5 mg10262
Sumatriptan 100 mg247140

[back to top]

Pain Relief at 2 Hours After Dose

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment (NCT00898677)
Timeframe: 2 hours after dose

,,,
InterventionParticipants (Number)
2-hour pain reliefNo 2-hour pain relief
Placebo6495
Rizatriptan 10 mg258127
Rizatriptan 5 mg9965
Sumatriptan 100 mg239148

[back to top]

Pain Free at 2 Hours After Dose

Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain). (NCT00898677)
Timeframe: 2 hours after dose

,,,
InterventionParticipants (Number)
2-hour Pain freedomNo 2-hour pain freedom
Placebo15139
Rizatriptan 10 mg155230
Rizatriptan 5 mg41123
Sumatriptan 100 mg127260

[back to top]

Nausea at 2 Hours After Dose

Patients who recorded the presence or absence of nausea 2 hours after dose (NCT00898677)
Timeframe: 2 hours after dose

,,,
Interventionparticipants (Number)
2-hour NauseaNo 2-hour Nausea
Placebo6891
Rizatriptan 10 mg95290
Rizatriptan 5 mg37127
Sumatriptan 100 mg128259

[back to top]

Functional Status at 2 Hours After Dose

Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest). (NCT00898677)
Timeframe: 2 hours after dose

,,,
InterventionParticipants (Number)
No functional disabilityMildly impairedSeverely impairedRequired bed rest
Placebo31593336
Rizatriptan 10 mg1601236042
Rizatriptan 5 mg52622723
Sumatriptan 100 mg1261426752

[back to top]

Pain Relief at 2 Hours During the Second Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the second migraine attack (NCT00899379)
Timeframe: 2 hours

,
InterventionParticipants (Number)
Reporting pain reliefNot reporting pain relief
Placebo2746
Rizatriptan 10 mg22863

[back to top]

Pain Relief at 2 Hours During the Third Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the third migraine attack (NCT00899379)
Timeframe: 2 hours

,
InterventionParticipants (Number)
Reporting pain reliefNot reporting pain relief
Placebo2154
Rizatriptan 10 mg20752

[back to top]

Pain Relief at 2 Hours During the First Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) at baseline to grades 0 or 1 (no headache or mild) at 2 hours after initial dosing for the first migraine attack (NCT00899379)
Timeframe: 2 hours

,
Interventionparticipants (Number)
Reporting pain reliefNot reporting pain relief
Placebo3052
Rizatriptan 10 mg24674

[back to top]

Pain Relief at 2 Hours During the Fourth Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the fourth migraine attack (NCT00899379)
Timeframe: 2 hours

,
InterventionParticipants (Number)
Reporting pain reliefNot reporting pain relief
Placebo3126
Rizatriptan 10 mg19065

[back to top]

Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age

Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 1 (no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose

,
Interventionparticipants (Number)
2-hour pain freedomNo 2-hour pain freedom
Placebo63223
Rizatriptan87197

[back to top]

Pain Freedom at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age

Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 1 (no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose

,
Interventionparticipants (Number)
2-hour pain freedomNo 2-hour pain freedom
Placebo94294
Rizatriptan126256

[back to top]

Pain Relief at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age

Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain relief was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 2 or 1 (mild or no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose

,
Interventionparticipants (Number)
2-hour pain reliefNo 2-hour pain relief
Placebo147139
Rizatriptan167117

[back to top]

Pain Relief at 2 Hours Post Dose in Participants Between 6 and 17 Years of Age

Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain relief was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 2 or 1 (mild or no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose

,
Interventionparticipants (Number)
2-hour pain reliefNo 2-hour pain relief
Placebo204184
Rizatriptan220162

[back to top]

Percentage of Participant's Migraine Attacks With Pain Freedom at 2 Hours Post Dose

Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom (PF) was defined as a reduction in severity from a rating of 5, 4, 3 or 2 (mild, moderate or severe pain) before the dose to a rating of 1 (no pain) at 2 hours after dosing. Pain intensity ratings were reported in diaries returned at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. PF at 2 hours was summarized as follows: the percentage of treated attacks with PF at 2 hours was calculated for each patient first, then the mean across all patients was calculated. (NCT01004263)
Timeframe: 2 hours post dose

Interventionpercentage of participant's attacks (Mean)
Rizatriptan46.3

[back to top]

Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post Dose

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants who discontinued due to an AE occurring within 14 days post dose are counted in this summary. (NCT01004263)
Timeframe: Up to 14 days post dose

Interventionparticipants (Number)
Rizatriptan14

[back to top]

Number of Participants With AEs Within 14 Days Post Any Dose

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants reported AEs in a diary and these were collected by the study site at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. AEs were assessed in a phone contact 14 days after the last dose of study medication. Participants with an AE occurring within 14 days after any dose administered during the study are counted once in this summary. (NCT01004263)
Timeframe: Up to 14 days post dose

Interventionparticipants (Number)
Rizatriptan400

[back to top]

Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants reported AEs in a diary and these were collected by the study site at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. Participants with an AE occurring within 24 hours after any dose administered during the study are counted once in this summary. (NCT01004263)
Timeframe: Up to 24 hours post dose

Interventionparticipants (Number)
Rizatriptan322

[back to top]

Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post Dose

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants who discontinued due to an AE occurring within 24 hours post dose are counted in this summary. (NCT01004263)
Timeframe: Up to 24 hours post dose

Interventionparticipants (Number)
Rizatriptan4

[back to top]

Favorable Response on Migraine-ACT

The Migraine-ACT is a 4-item scale with yes/no responses. A score of 3 or more is considered favorable. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The Migraine-ACT is reported as a binary measure (3 or more positive responses). The outcome presented included the percentage with a score of 3 or more, and the Odds ratio comparing the two treatments. (NCT01086358)
Timeframe: 6 months

Interventionpercentage of favorable responses (Mean)
Arm 1 - Triptan46
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm71

[back to top]

Workplace Productivity and Activity Impairment Scale (WPAI).

The primary outcome measure was lost productivity (workplace productivity + non-workplace activity time) as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months

Interventionhours (Mean)
Arm 1 - Triptan4.15
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm2.44

[back to top]

Lost Workplace Productivity

This outcome measure was lost workplace productivity as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months

Interventionhours (Mean)
Arm 1 - Triptan2.25
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm1.23

[back to top]

Lost Activity Time

This outcome measure was lost activity time as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 Months

Interventionhours (Mean)
Arm 1 - Triptan1.89
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm1.22

[back to top] [back to top]

Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug

Headache severity was rated on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain) immediately before initial dose and at 2 hours thereafter. Pain relief was defined as a reduction of headache severity from grades 2/3 at baseline to 0/1. (NCT01286207)
Timeframe: 2 hours after initial dose of test drug

Interventionpercent of headaches (Median)
Rizatriptan 5 mg80
Rizatriptan 10 mg89.5
Standard Care69.6

[back to top]

Number of Participants Who Discontinued Due to Clinical Adverse Experiences

(NCT01286207)
Timeframe: Up to 12 months

,,
Interventionparticipants (Number)
Discontinued due to CAEsNot discontinued due to CAEs
Rizatriptan 10 mg37797
Rizatriptan 5 mg26685
Standard Care7327

[back to top] [back to top]

Number of Participants With Serious Clinical Adverse Experiences

Serious clinical adverse experiences (CAEs) are any adverse events (AEs) occurring at any dose that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT01286207)
Timeframe: Up to 12 months

,,
Interventionparticipants (Number)
With Serious CAEsWithout Serious CAEs
Rizatriptan 10 mg17817
Rizatriptan 5 mg13698
Standard Care10324

[back to top]

Episodes With Complete Relief of Unsteadiness/Dizziness Vestibular Symptoms

The outcome was the number of episodes in which complete relief of symptoms of unsteadiness/dizziness (rating 0) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo2
Rizatriptan12

[back to top]

Episodes With Complete Relief of Vertigo as Vestibular Symptom

The number of episodes in which complete relief of vertigo symptoms (rating 0) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo35
Rizatriptan56

[back to top]

Episodes With Headache Reduced From Moderate/Severe to None/Mild

The outcome was the number of episodes in which a reduction of headache symptoms (rating 0) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo38
Rizatriptan44

[back to top]

Episodes With Headache Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication

After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo46
Rizatriptan94

[back to top]

Episodes With Nausea/Vomiting Reduced From Moderate/Severe to None/Mild

The outcome was the number of episodes in which a reduction of symptoms (rating 0/1) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo50
Rizatriptan67

[back to top]

Episodes With Nausea/Vomiting Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication

After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo57
Rizatriptan101

[back to top]

Episodes With Photophobia/Phonophobia Reduced From Moderate/Severe to None/Mild

The outcome was the number of episodes in which a reduction of symptoms (rating 0/1) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo33
Rizatriptan59

[back to top]

Episodes With Photophobia/Phonophobia Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication

After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo45
Rizatriptan95

[back to top]

Episodes With Sensitivity to Motion Reduced From Moderate/Severe to None/Mild

The outcome was the number of episodes in which a reduction of sensitivity to motion symptoms (rating 0/1) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo19
Rizatriptan39

[back to top]

Episodes With Sensitivity to Motion Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication

After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo42
Rizatriptan95

[back to top]

Episodes With Sustained Reduction in Severity of Dizziness/Unsteadiness From Moderate/Severe to None/Mild Without Additional Medication

Episodes in which participants achieved reduction of symptoms (from rating 2-3 to 0-1). After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo41
Rizatriptan90

[back to top]

Episodes With Sustained Reduction in Severity of Vertigo From Moderate/Severe to None/Mild Without Additional Medication

Episodes in which participants achieved reduction of symptoms (from rating 2-3 to 0-1). After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 24 hours after taking study medication

InterventionEpisodes (Number)
Placebo54
Rizatriptan97

[back to top]

Episodes With Symptoms of Unsteadiness/Dizziness Reduced From Moderate/Severe to None/Mild

Episodes of unsteadiness/dizziness in which a reduction in symptom severity from moderate/severe (rating 2/3) to none/mild rating (0/1) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo11
Rizatriptan29

[back to top]

Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild

Episodes in which a reduction in symptom severity from moderate/severe (rating 2/3) at time of taking study medication to none/mild rating (0/1) was achieved. After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities). (NCT02447991)
Timeframe: 1 hour after taking study medication

InterventionEpisodes (Number)
Placebo50
Rizatriptan73

[back to top] [back to top]

Satisfaction With Treatment

Treatment Satisfaction Questionnaire for Medication (TSQM) assessed four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction). (NCT02447991)
Timeframe: 48 hour after taking study medication

,
Interventionscore on a scale (Mean)
EffectivenessSide EffectsConvenienceOverall Satisfaction
Placebo37.278.870.045.9
Rizatriptan49.781.671.058.2

[back to top]

Side Effects

Number of adverse events experienced by participants. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 categorizes all domains of physical and psychological side effects, grading them 1-mild, 2-moderate, 3-severe, 4-life threatening, 5-death. (NCT02447991)
Timeframe: 48 hour after taking study medication

,
InterventionAdverse Events (Number)
FatigueSleepiness/DrowsinessUpset Stomach, nausea, vomitingConstipation or diarrheaHearth rhythm problemsChest pain or decreased exercise toleranceSwelling or puffinessFever or chillsWorsening of dizziness or gaitWorsening of headacheAtaxiaSpeech problemsWeakness of arms/legs/face or loss of sensationAgitationAnxietySerious adverse effectsDiscontinuation due to adverse effects
Placebo711832100391151500
Rizatriptan44511935034151343751200

[back to top]

Percentage of Subjects With Absence of Most Bothersome Symptom

Absence of most bothersome symptom, defined at the onset of migraine. AXS-07 vs Placebo. (NCT03896009)
Timeframe: Hour 2 following dose administration

InterventionParticipants (Count of Participants)
AXS-07158
Placebo51

[back to top]

Percentage of Subjects Reporting Headache Pain Freedom

Absence of headache pain. AXS-07 vs Placebo. (NCT03896009)
Timeframe: Hour 2 following dose administration

InterventionParticipants (Count of Participants)
AXS-0785
Placebo14

[back to top]